Using the subcutaneous ectopic MN-MCA1 sarcoma model, p.o. delivery of KCL-HO-1i and i.p. delivery of gemcitabine in mice bearing established MN-MCA1 tumors also combined synergistically to deliver tumor control in this model (Figure 6C). This evidence concerns the gene HMOX1 and sarcoma.